BiotechTube
Vivlion

Vivlion

Regensburg, Germany· Est.
vivlion.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $16.3M

Overview

Vivlion is a private, pre-revenue platform company developing next-generation CRISPR screening tools through its proprietary 3Cs (Covalently-Closed-Circular-synthesized) manufacturing technology. This technology addresses critical limitations of conventional library production by eliminating PCR-induced bias, resulting in libraries with superior uniformity and completeness. The company's offerings include single and combinatorial sgRNA libraries, as well as full-service screening and bioinformatics, enabling more efficient genetic screens with less cell material. Vivlion's platform is positioned to enhance target discovery across various therapeutic areas, particularly in oncology.

Oncology

Technology Platform

Proprietary PRCISR™ technology based on 3Cs (Covalently-Closed-Circular-synthesized) manufacturing process for producing highly uniform, PCR-bias-free CRISPR sgRNA libraries. Enables single and combinatorial genetic screens with high efficiency and low cell material requirements.

Funding History

2
Total raised:$16.3M
Series A$12M
Seed$4.3M

Opportunities

The growing demand for efficient, high-quality CRISPR screening tools in pharmaceutical R&D presents a significant opportunity.
Vivlion's ability to enable combinatorial screens for genetic interactions positions it at the forefront of a key trend in target discovery, particularly in complex diseases like cancer.
The technology's efficiency with limited cell material also opens the valuable market of primary and stem cell research.

Risk Factors

Vivlion operates in a highly competitive and fast-evolving market dominated by large reagent suppliers, risking being out-marketed.
Its technology, while differentiated, could be supplanted by new CRISPR systems or screening modalities.
As a young, private company, it also faces scaling challenges and dependence on continued biopharma R&D investment.

Competitive Landscape

Vivlion competes with large life science tool companies (e.g., Merck KGaA, Horizon Discovery/Takara Bio, Synthego) that offer CRISPR libraries and services, as well as academic core facilities. Its key differentiator is the claimed superior uniformity of its libraries via its 3Cs technology, which allows for smaller, more efficient screens compared to standard PCR-amplified libraries.

More companies in CRISPR / Gene Editing →More companies in Germany →